The use of methylene blue in the treatment of anaphylactic shock induced by compound 48/80: Experimental studies in rabbits

Shock

Volumn 23, Issue 6, 2005, Pages 582-587

  Buzato, Marcelo A S ^a   Viaro, Fernanda ^a   Piccinato, Carlos E ^a   Evora, Paulo R B ^a,b  

^a UNIVERSITY OF SÃO PAULO   (Brazil)

^b NONE   (Brazil)

Author keywords

Anaphylactic shock; Methylene blue; Nitric oxide

Indexed keywords

COMPOUND 48-80; METHYLENE BLUE; NITRATE; NITRIC OXIDE;

ABDOMINAL AORTA; ANAPHYLACTIC SHOCK; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTERY ENDOTHELIUM; ARTICLE; DRUG EFFECT; DRUG EFFICACY; DRUG SAFETY; MEAN ARTERIAL PRESSURE; NONHUMAN; RABBIT; SURVIVAL;

ADRENAL CORTEX HORMONES; ANAPHYLAXIS; ANIMALS; ARTERIES; BLOOD PRESSURE; DOSE-RESPONSE RELATIONSHIP, DRUG; ENDOTHELIUM, VASCULAR; ENZYME INHIBITORS; EPINEPHRINE; HYPOTENSION; MALE; METHYLENE BLUE; NITRATES; NITRIC OXIDE; NITRITES; P-METHOXY-N-METHYLPHENETHYLAMINE; RABBITS; TIME FACTORS;

EID: 18744380989     PISSN: 10732322     EISSN: None     Source Type: Journal    
DOI: 10.1097/01.shk.0000161391.46688.93     Document Type: Article

References (32)

1. Kilbourn RG, Traber DL, Szabo C: Nitric oxide and shock. Dis Mon 43:277-348, 1997.
2. Palmer RMJ, Moncada S: Inhibition of nitric oxide synthesis in septic shock: how much is beneficial? Lancet 338:1555-1557, 1991.
3. Ekin ST, Pearson PJ, Evora PRB, Schaff HV: Pseudomonas endotoxin produces endothelium-dependent vasodilation of canine arteries in vitro: a possible mechanism of early hypotension in pseudomonas septicemia. FASEB J 6:A1813, 1992.
4. Paya D, Gray GA, Stoclet JC: Effects of methylene blue on blood pressure and reactivity to norepinephrine in endotoxemic rats. J Cardiovasc Pharmacol 21:926-930, 1993.
5. Evora PRB, Seccombe JF, Pearson PJ, Schaff HV: O papel do óxido nítrico e perspectivas terapêuticas na sepse bacteriana. Rev Bras Terap Intens 6:105-107, 1994.
6. Petros A, Lamb G, Leone L, Moncada S, Bennett D, Vallance P: Effects of a nitric synthase inhibitor in humans with septic shock. Cardiovasc Res 28:34-39, 1994.
7. Daemen-Gubbels CR, Groeneveld PH, Groeneveld AB, van Kamp GJ, Bronsveld W, Thijs LG: Methylene blue increases myocardial function in septic shock. Crit Care Med 23:1363-1370, 1995.
8. Keaney JF Jr, Puyana JC, Francis S, Loscalzo JF, Stamler JS, Loscalzo J: Methylene blue reverses endotoxin-induced hypotension. Circ Res 74:1121-1125, 1994.
9. Marczin N, Tekeres M, Salzman AL, Szabo C: Methylene blue infusion in septic shock. Crit Care Med 23:1936-1938, 1995.
10. Mayer J, Hajek R, Vorlicek J, Tomiska M: Sepsis and septic shock. Definitions and pathophysiology. Support Care Cancer 3:106-110, 1995.
11. Preiser JC, Lejeune P, Roman A, Carlier E, De Backer D, Leeman M, Kahn RJ, Vincent JL: Methylene blue administration in septic shock: a clinical trial. Crit Care Med 23:259-264, 1995.
12. Schneider F: Methylene blue infusion in septic shock. Crit Care Med 23:1935-1936, 1995.
13. Zhang H, Rogiers P, Preiser JC, Spapen H, Manikis P, Metz G, Vincent JL: Effects of methylene blue on oxygen availability and regional blood flow during endotoxic shock. Crit Care Med 23:1711-1721, 1995.
14. Osada S, Ichiki H, Oku H, Ishiguro K, Kunitomo M, Semma M: Participation of nitric oxide in mouse anaphylactic hypotension. Eur J Pharmacol 252:347-350, 1994.
15. Mitsuhata H, Shimizu R, Yokoyama MM: Role of nitric oxide in anaphylactic shock. J Clin Immunol 15:277-283, 1995.
16. Mitsuhata H, Takeuchi H, Saitoh J, Hasome N, Horiguchi Y, Shimizu R: An inhibitor of nitric oxide synthase, N-ω-nitro-L-arginine-methyl ester, attenuates hypotension but does not improve cardiac depression in anaphylaxis in dogs. Shock 3:447-453, 1995.
17. Evora PRB, Ribeiro PJF, de Andrade JC: Methylene blue administration in SIRS after cardiac operations. Ann Thorac Surg 63:1212-1213, 1997.
18. Evora PRB, Roselino CH, Schiavetto PM: Methylene blue in anaphylatic shock. Ann Emerg Med 30:240, 1997.
19. Evora PRB, Roselino CH, Schiavetto PM: Utilização do azul de metileno no tratamento do choque anafilático. Uma proposiçã o clínica e apresentação de três casos. Rev Bras Terap Intens 9:126-131, 1997.
20. Evora PRB: Should methylene blue be the drug of choice to treat vasoplegias caused by cardiopulmonary bypass and anaphylactic shock? J Thorac Cardiovasc Surg 119:632-634, 2000.
21. Evora PR, Levin RL: Methylene blue as drug of choice for catecholamine-refractory vasoplegia after cardiopulmonary bypass. J Thorac Cardiovasc Surg 127:895-896, 2004.
22. Andrade JCS, Batista Filho ML, Evora PRB, Tavares JR, Buffolo E, Ribeiro EE, Silva LA, Teles CA, Petrizzo A, Barata Filho VV, Duprat R: Utilização do azul de metileno no tratamento da síndrome vasoplégica após cirurgia cardíaca. Rev Bras Cirurg Cardiovasc 11:107-114, 1996.
23. Levin RL, Degrange MA, Bruno GF, Del Mazo CD, Taborda DJ, Griotti JJ, Boullon FJ: Methylene blue reduces mortality and morbidity in vasoplegic patients after cardiac surgery. Ann Thorac Surg 77:496-499, 2004.
24. Evora PRB, Oliveira Neto AM, Duarte NM, Vicente WV: Methylene blue as treatment for contrast medium-induced anaphylaxis. J Postgrad Med 48:327, 2002.
25. Oliveira Neto AM, Duarte NM, Vicente WV, Viaro F, Evora PR: Methylene blue: an effective treatment for contrast medium-induced anaphylaxis. Med Sci Monit 9:CS102-CS106, 2003.
26. van Amsterdan JGC, van den Berg C, Zuidema J, te Biesebeek JD, Rokos H: Effects of septicaemia on the plasma levels of biopterin and nitric oxide metabolites in rats a rabbits. Biochem Pharmacol 52:1447-1451, 1996.
27. de Werra I, Jaccard C, Corradin SB, Chiolero R, Yersin B, Gallati H, Assicot M, Bohuon C, Baumgartner JD, Glauser MP, Heumann D: Cytokines, nitrite/nitrate, soluble tumor necrosis factor receptors, and procalcitonin concentrations: comparisons in patients with septic shock, cardiogenic shock, and bacterial pneumonia. Crit Care Med 25:607-613, 1997.
28. Spack L, Havens PL, Griffith OW: Measurements of total plasma nitrite and nitrate in pediatric patients with the systemic inflammatory response syndrome. Crit Care Med 25:1071-1078, 1997.
29. Takakuwa T, Endo S, Inada K, Kasai T, Yamada Y, Ogawa M: Assessment of inflammatory cytokines, nitrate/nitrite, type II phospholipase A2, and soluble adhesion molecules in systemic inflammatory response syndrome. Res Commun Mol Pathol Pharmacol 98:43-52, 1997.
30. Mitaka C, Hirata Y, Yokoyama K, Wakimoto H, Hirokawa M, Nosaka T, Imai T: Relationships of circulating nitrite/nitrate levels to severity and multiple organ dysfunction syndrome in systemic inflammatory response syndrome. Shock 19:305-309, 2003.
31. Miller MJ, Grisham MB: Nitric oxide as a mediator of inflammation? You have better believe it. Mediators Inflamm 4:387-396, 1995.
32. Ellis G, Adatia I, Yazdanpanah M, Makela SK: Nitrite and nitrate analyses: a clinical biochemistry perspective. Clin Biochem 31:195-220, 1998.